Ligand Pharmaceuticals (LGND) Competitors

Ligand Pharmaceuticals (NASDAQ:LGND) and ADMA Biologics (NASDAQ:ADMA) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Do institutionals and insiders believe in LGND or ADMA?

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has preferable earnings & valuation, LGND or ADMA?

ADMA Biologics has higher revenue and earnings than Ligand Pharmaceuticals. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$187.58M	16.01	-$4.03M	-$4.00	-38.32
ADMA Biologics	$426.45M	9.87	$197.67M	$0.86	20.50

Do analysts recommend LGND or ADMA?

Ligand Pharmaceuticals presently has a consensus target price of $157.00, indicating a potential upside of 2.44%. ADMA Biologics has a consensus target price of $27.67, indicating a potential upside of 56.93%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Does the media refer more to LGND or ADMA?

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than ADMA Biologics. MarketBeat recorded 19 mentions for Ligand Pharmaceuticals and 16 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 1.60 beat Ligand Pharmaceuticals' score of 0.63 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	14 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, LGND or ADMA?

Ligand Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500.

Is LGND or ADMA more profitable?

ADMA Biologics has a net margin of 44.06% compared to Ligand Pharmaceuticals' net margin of -40.44%. ADMA Biologics' return on equity of 41.01% beat Ligand Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	-40.44%	-9.21%	-8.09%
ADMA Biologics	44.06%	41.01%	28.47%

Summary

ADMA Biologics beats Ligand Pharmaceuticals on 11 of the 17 factors compared between the two stocks.